Similar articles

• Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.

  Marksteiner J, Hinterhuber H, Humpel C. Marksteiner J, et al. Drugs Today (Barc). 2007 Jun;43(6):423-31. doi: 10.1358/dot.2007.43.6.1067341. Drugs Today (Barc). 2007. PMID: 17612711 Review.
• Will CSF analysis become routine in people with memory complaints?

  Gauthier S. Gauthier S. Lancet Neurol. 2009 Jul;8(7):595-6. doi: 10.1016/S1474-4422(09)70145-0. Epub 2009 Jun 10. Lancet Neurol. 2009. PMID: 19523878 No abstract available.
• Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.

  Dean RA, Shaw LM. Dean RA, et al. Clin Chem. 2010 Jan;56(1):7-9. doi: 10.1373/clinchem.2009.134692. Epub 2009 Nov 19. Clin Chem. 2010. PMID: 19926774 No abstract available.
• Biomarkers for the early diagnosis of Alzheimer's disease.

  de Leon MJ, Klunk W. de Leon MJ, et al. Lancet Neurol. 2006 Mar;5(3):198-9. doi: 10.1016/S1474-4422(06)70357-X. Lancet Neurol. 2006. PMID: 16488371 No abstract available.
• Advances on biological markers in early diagnosis of Alzheimer disease.

  Padovani A, Borroni B, Di Luca M. Padovani A, et al. Adv Clin Chem. 2005;39:107-29. doi: 10.1016/s0065-2423(04)39004-9. Adv Clin Chem. 2005. PMID: 16013669 Review. No abstract available.